Abstract-Concerns have been raised about the adverse effect of fructose on blood pressure. International dietary guidelines, however, have not addressed fructose intake directly. A systematic review and meta-analysis was conducted to assess the effect of fructose in isocaloric exchange for other carbohydrates on systolic, diastolic, and mean arterial blood pressures. Studies were identified using Medline, Embase, and Cochrane databases (through January 9, 2012). Human clinical trials of isocaloric oral fructose exchange for other carbohydrate sources for Ն7 days were included in the analysis. Data were pooled by the generic inverse variance method using random-effects models and expressed as mean differences with 95% CI. Heterogeneity was assessed by the Q-statistic and quantified by I 2 . Study quality was assessed using the Heyland Methodological Quality Score. Thirteen isocaloric (nϭ352) and 2 hypercaloric (nϭ24) trials met the eligibility criteria. Overall, fructose intake in isocaloric exchange for other carbohydrates significantly decreased diastolic (mean difference: Ϫ1.54 [95% CI: Ϫ2.77 to Ϫ0.32]) and mean arterial pressure (mean difference: Ϫ1.16 [95% CI: Ϫ2.15 to Ϫ0.18]). There was no significant effect of fructose on systolic blood pressure (mean difference: Ϫ1.10 [95% CI: Ϫ2.46 to 0.44]). The hypercaloric fructose feeding trials found no significant overall mean arterial blood pressure effect of fructose in comparison with other carbohydrates. To confirm these results, longer and larger trials are needed. Contrary to previous concerns, we found that isocaloric substitution of fructose for other carbohydrates did not adversely affect blood pressure in humans. 
intervention studies, however, have shown conflicting results: fructose has been shown to increase and decrease BP. [13] [14] [15] [16] [17] [18] Few nutrition guidelines address fructose directly. BP guidelines have not addressed the effect of fructose or any other sugars on BP in their guidelines. 19, 20 Only the American Heart Association, Canadian Diabetes Association, and American Diabetes Association have addressed fructose directly but only based on proposed lipid effects. [21] [22] [23] [24] To assess whether fructose has an adverse effect on BP and build an evidence base for dietary guidelines, we conducted a systematic review and meta-analysis of controlled feeding trials investigating the effects of fructose on BP.
Methods
The Cochrane Handbook for Systematic Reviews of Interventions was used as a guideline for this meta-analysis. 25 Reporting of results followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 26 
Study Strategy
Relevant controlled feeding trials were identified using Medline, Embase, and the Cochrane Central Register of Controlled Trials through January 9, 2012, using the search terms and Boolean operators: "fructose AND (blood pressure OR BP OR SBP OR DBP OR mean arterial pressure OR MAP)." Manual searches of references cited by published studies also supplemented the database search.
Inclusion Criteria
Human trials that investigated the effect of isocaloric or hypercaloric fructose compared with other carbohydrate sources (CH 2 O) on SBP, diastolic BP (DBP), or mean arterial BP (MAP) were included. Investigators must have administered fructose and control CH 2 O orally for a minimum of 7 days. We excluded trials in which fructose was administered exclusively as sucrose or high-fructose corn syrup, because this did not permit us to isolate the effect of fructose. Studies were considered to be "isocaloric" when the fructose intervention was compared with its CH 2 O comparator under iso-energetic conditions (ie, even if both arms were hypocaloric relative to weight maintenance requirements) and "hypercaloric" when the oral fructose was provided as a supplement to the control diet, providing excess energy relative to the control diet alone. No restriction was placed on language.
Data Extraction
Studies that met the inclusion criteria had their study characteristics and results extracted by 3 independent reviewers (V.H., L.C., and D.D.W.). These data included study design, randomization, blinding, sample characteristics, comparator, dose, follow-up, fructose form, compliance measures, and macronutrient profile of the background diet. Disagreements were resolved by consensus and when necessary with J.L.S. All of the disagreements were concerning the Heyland Score. 17, 27, 28 Start and end meanϮSD for SBP, DBP, and MAP were recorded when provided, as well as any reported P values for differences between start and end values and between treatments. MAP was calculated for studies that reported SBP and DBP end points but not MAP using the following formula: MAP ϭ 2 ⁄3 DBP ϩ 1 ⁄3 SBP. The SDs for these calculated MAPs were calculated using the following formula:
where N is the sample size, and s is the SD. All of the data were entered in triplicate into a spreadsheet template (Microsoft Excel, Microsoft Corp). Trials that did not report either change-from-start differences within or between treatments or end differences between treatments had these imputed from the available data using standard formulas. 25 Authors were contacted, when possible, to request additional information. Missing SD values were imputed from the pooled SD from other published reports. 29 The quality of each study was assessed using the Heyland Methodological Quality Score (MQS). 30 Studies could receive a maximum score of 13 points. Studies with a score of Ն8 were considered high quality. Points were awarded based on the quality of the study methods, sample selection and follow-up, and intervention.
Statistical Analyses
Data were analyzed using Review Manager (RevMan) version 5.0.25 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark). Pooled analyses for isocaloric and hypercaloric fructose feeding trials were conducted using the Generic Inverse Variance method using random-effects models. Analyses were stratified by diabetes mellitus status. Our overall analysis combined the nondiabetic with the prediabetic/diabetic participants. Mean end points of SBP, DBP, and MAP were compared between fructose and its respective CH 2 O comparator. Data were expressed as mean differences (MD) with 95% CIs. To mitigate the unit-of-analysis error from including trials with multiple intervention arms, we combined arms to create single pairwise comparisons. Because correlation coefficients could not be derived for paired analyses of crossover trials, 31 we made assumptions about the degree of correlation between treatment and control end values. We assumed a conservative degree of correlation of 0.50, with sensitivity analyses done at 2 additional levels, 0.25 and 0.75. A 2-sided P value Ͻ0.05 was set as the level of significance for an effect. The Q-statistic assessed and I 2 quantified the interstudy heterogeneity with significance set at PϽ0.10. An I 2 Ն50% indicated "substantial" heterogeneity, and Ն75% indicated "considerable" heterogeneity. Sources of heterogeneity were explored using a priori subgroup analyses of CH 2 O comparator (starch, glucose, sucrose, and high-fructose corn syrup), dose (Canadian Diabetes Association threshold of Յ60 g/d or Ͼ60 g/d), 22 follow-up (Յ4 weeks or Ͼ4 weeks), fructose form (fluid, mixed, or solid), study quality (MQS Ͻ8 or Ն8), randomization (yes or no), and study design (crossover or parallel). Systematic removal of studies was conducted during sensitivity analyses to determine whether any single study exerted an undue influence on the overall results. Subgroup analyses were conducted only for nondiabetic participants, because only 2 trials, 14, 17 with conflicting results, had been undertaken in prediabetic/diabetic participants.
Metaregressions were performed to assess the significance of subgroup effects (Stata 11.2, StataCorp, College Station, TX). Publication bias was investigated by visual inspection of funnel plots and formally tested using Egger and Begg tests. Figure 1 shows the flow of literature. The search identified 319 reports, 303 of which were determined to be irrelevant on review of the titles and abstracts. The remaining 16 reports were reviewed in full. A total of 11 reports were selected for analysis, providing data for 15 trials: 13 isocaloric 14, 15, 17, 27, 28, [32] [33] [34] [35] [36] and 2 hypercaloric feeding trials, 27, 37 with a median follow-up of 4.0 weeks (range: 15.5 days to 10 weeks).
Results

Search Results
Study Characteristics
The There were 2 reported hypercaloric trials. Both hypercaloric trials used a nonrandomized, crossover design. Both administered fructose in a fluid format at a median dose of Ϸ143 g/d (ϩ18% to 25% E). The background diet consisted of 55% E CH 2 O, 15% E protein, and 30% E fat in both trials. One of the trials used an automated technique to measure BP and the other did not specify. Both trials did not specify the type of end point for BP. Median follow-up was 7 weeks (range: 4 -10 weeks). Both hypercaloric trials scored as low quality with an MQS Ͻ8.
Isocaloric Feeding Trials
Systolic BP Isocaloric exchange of fructose for other CH 2 O had no effect on SBP in the overall analysis or in analyses stratified by diabetes status (Figure 2 ). There was significant evidence of interstudy heterogeneity in the prediabetes/diabetes mellitus stratum. The use of broader correlation coefficients (0.25 and 0.75) did not alter these main findings; however, using correlation coefficient of 0.75, interstudy heterogeneity became significant in the overall analysis (data not shown). Sensitivity analyses in which each individual study was systematically removed, and the effect estimate recalculated without it, showed that the removal of Madero et al 34 resulted in a significant SBP-lowering effect in the nondiabetic stratum and the overall analysis.
To conserve power, a priori subgroup analyses were carried out using data only from isocaloric trials in nondiabetes to test for possible fructose effect modifiers on SBP by study design characteristics ( Figure S1 , please see the online-only Data Supplement). We found no significant effect modifiers of SBP by metaregression analysis. There was significant evidence of interstudy heterogeneity, however, if the study had a parallel study design or an MQS score Ͻ8 (I 2 Ն61%; PϽ0.10).
Diastolic BP
Isocaloric exchange of fructose for other CH 2 O had a significant DBP-reducing effect in the overall analysis and in the nondiabetes stratum but no significant effect in the prediabetes/diabetes mellitus stratum (Figure 3 ). Only the prediabetes/ diabetes mellitus stratum showed no significant evidence of interstudy heterogeneity. 
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coefficients (0.25 and 0.75) did not alter these main findings; however, using correlation coefficient of 0.25, the interstudy heterogeneity in the overall analysis became nonsignificant, and using a correlation coefficient of 0.75, interstudy heterogeneity became significant in the prediabetic/diabetic stratum (data not shown). Sensitivity analyses in which each individual study was systematically removed showed that the removal of Stanhope et al 27 or Brymora et al 33 resulted in a loss of significance in the overall analysis and in the nondiabetic stratum.
A priori subgroup analyses were carried out using data only from isocaloric trials in nondiabetes to test for possible fructose effect modifiers on DBP by study design character- 27 included a 2-wk baseline isocaloric period followed by 8 wk of hypercaloric feeding and finally followed by 2 wk of isocaloric feeding, for a total study duration of 10 wk. Thus, we considered the comparison between glucose and fructose arms at week 10 as the isocaloric trial and the comparison of fructose at week 8 with the control diet at week 0 as the hypercaloric trial. †N indicates normal; CKD, chronic kidney disease; HI, hyperinsulinemic; OW, overweight; OB, obese; IGT, impaired glucose-tolerant; DM2, type 2 diabetes mellitus; PM, postmenopausal. ‡C indicates crossover and P indicates parallel.
§Yes indicates that all food was prepared and provided by a metabolic kichen at the research institution; partial indicates that some food was prepared and provided by investigators; no indicates supplements of fructose and other carbohydrate on top of an ad libitum diet.
ʈDoses preceded by "Ϸ"represent average doses; % E indicates percentage of total daily caloric intake. ¶Fructose was provided one of 3 forms: (1) liquid, where all or most of the fructose was provided as a beverage or crystalline fructose to be added to liquid for consumption; (2) solid, where all or most of the fructose was provided in prepared food; or (3) mixed, a combinaton of liquid and solid forms of fructose.
#Comparator refers to the reference carbohydrate (starch, glucose, sucrose, or high-fructose corn syrup). **Study quality was assessed by the Heyland Methodological Quality Score (MQS).
istics ( Figure S2 ). We found no significant effect modifiers of DBP by metaregression analysis. Unexplained interstudy heterogeneity was seen in studies that used glucose as a CH 2 O comparator, have a follow-up period Ͼ4 weeks, administered fructose in either a fluid or mixed format, have either a crossover or a parallel study design, or have an MQS score Ն8 (I 2 Ն50%; PՅ0.10).
Mean Arterial Pressure
Isocaloric exchange of fructose for other CH 2 O had a significant MAP-reducing effect in the overall analysis and in the nondiabetes stratum but no significant effect in the prediabetes/diabetes mellitus stratum (Figure 4 ). Significant evidence of interstudy heterogeneity was seen across all 3 of the strata (I 2 Ն97%; PՅ0.10). The use of broader correlation coefficients (0.25 and 0.75) did not alter these findings. Sensitivity analysis in which each individual study was systematically removed showed that the removal of Madero et al, 34 Silbernagel et al, 35 or Koh et al 17 resulted in the loss of significance in the overall analysis. A priori subgroup analyses were carried out using data from only isocaloric trials in nondiabetes to explore effect modifiers of fructose on MAP ( Figure S3 ). We found no significant effect modifiers of MAP by metaregression analysis. Unexplained interstudy heterogeneity remained in these analyses (I 2 Ն53%; PՅ0.01).
Hypercaloric Feeding Trials
The 2 trials that reported hypercaloric fructose feeding showed conflicting MAP results, with no significant overall effect and evidence of interstudy heterogeneity. Sensitivity analysis using a correlation coefficient of 0.25 showed the summary effect to be significant (Pϭ0.03). 
Discussion
This meta-analysis of 13 isocaloric controlled feeding trials (nϭ352) with a median follow-up of 4 weeks found a significant DBP-and MAP-lowering effect when fructose was substituted for other carbohydrates but no effect on SBP. Hypercaloric fructose feeding did not significantly affect MAP. The present study is in agreement with prospective cohort studies 12 in failing to demonstrate an adverse effect of fructose on BP but at odds with acute clinical studies and animal models. Acute clinical studies have reported an increase in BP after fructose intake, 13, 16, 18 and rat studies have consistently shown that chronic high fructose intake raises SBP. [7] [8] [9] [10] This discrepancy between the results of our study and those of observational and intervention studies may be explained by heterogeneous conditions of BP measurement. Studies included in our systematic review did not specifically measure postprandial BP, 16, 18 at which time the adverse effects of fructose on BP have been most consistently shown in humans 16, 18 and laboratory rats. [7] [8] [9] [10] Furthermore, although our analysis suggests that casual BP is not elevated in response to longer-term fructose consumption, most of these studies investigated BP after an overnight fast when fructose may have been completely metabolized. Because intermittent elevations of BP are a risk factor for permanent hypertension, it may be beneficial for future studies to collect ambulatory BP measurements to better elucidate the effect of fructose on BP.
Fructose is proposed to raise BP via increasing uric acid production, which exerts hemodynamic effects, such as increased oxidative stress, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system. 4, 5 As a proof of concept, this mechanism was investigated directly in humans. Perez-Pozo et al 38 reported a randomized, 2-week crossover trial in which participants were fed 200 g/d of fructose and then randomized to either allopurinol, a xanthine oxidase inhibitor that inhibits the production of uric acid, or placebo for 2 weeks. Allopurinol was shown to prevent the fructose-induced phenotype of raised uric acid and BP. The authors concluded that the excessive fructose intake induced hypertension via elevated uric acid. However, 200 g of fructose is more than twice the 95th percentile of intake in the United States, 39 and the treatment effect of fructose was not compared with another source of carbohydrate under isocaloric conditions. We did not see such an effect in the present analysis. Five of the isocaloric trials that are included in our analysis that measured uric acid showed no significant change 15, 17, [33] [34] [35] ; however, the fructose dose in these studies was Ͻ200 g and when compared with other sources of carbohydrates. Whether these mechanisms are sufficient to exert chronic and clinically significant effects on BP in humans is uncertain.
Dose remains an important consideration in the interpretation of our analyses. The discrepancy between our results and those of Perez-Pozo et al 38 and animal models 7-10 may be explained by differences in fructose dose. Whereas the median fructose dose in the available isocaloric trials included in our meta-analysis was Ϸ78.5 g/d (range: 53-182 g/d), or Ϸ20.5% of energy (range: Ϸ9% to 25%), it was well below that used to induce BP increases in the Perez-Pozo et al 38 study (200 g) and animal models (Ϸ60% E). [7] [8] [9] [10] This evidence for a BP-raising effect is derived from trials of fructose doses that are well above the Ͼ95th percentile of intake (87 g/d) in the United States, according to the National and Health and Nutrition Examination Survey III. 39 Even for the group with the highest level of exposure, males and females aged 19 to 22 years, of whom Յ10% consume Ն100 g/d, 39 it is difficult to make generalizations. There is a clear need for larger and longer trials of fructose feeding at generalizable doses (Ͻ87 g/d) to confirm whether "realworld" fructose exposure contributes to the burden of hypertension and by association vascular and renal disease.
We found no significant effect modifiers of fructose on SBP, DBP, or MAP. In a previous meta-analysis on the effect of fructose on triglycerides in type 2 diabetes mellitus, we reported significant effect modification by dose (Ͼ60 g/d), follow-up (Ͼ4 weeks), and comparator (starch). 40 Livesey and Taylor, 41 in their meta-analysis on the effect of fructose on triglycerides, glycated hemoglobin, and body weight, also reported significant effect modification by dose (Ͼ50 g/d and Ͼ100 g/d for postprandial and fasting triglycerides, respectively). We did not see similar sources of effect modification in our meta-analysis. Substantial interstudy heterogeneity remained unexplained in our analysis. Other unmeasured sources of heterogeneity across the available trials need to be considered, including differences in techniques of BP measurement, whether BP was obtained as a primary or secondary end point, and different efficiencies of fructose absorption across different age groups. 42, 43 Because of insufficient variability, we could not formally test for heterogeneity in these domains.
There are several limitations to our work. First, the external validity of the BP effects remains a concern given that the participant pool was small and, of the total 352 participants, only 19 were classified as having diabetes mellitus or prediabetes; therefore, our conclusions may not be generalizable to the population of those living with these conditions. Second, only 2 hypercaloric studies assessed MAP, and only 1 of the hypercaloric studies reported SBP and DBP. Third, the data provided by Madero et al 34 must be interpreted carefully. Although this study met all of our specified inclusion criteria, they used fruits as a vehicle for fructose administration. Fruits contain compounds such as vitamin C, quercetin, and resveratrol that may alter the metabolic effects of fructose. Fourth, the lack of reporting of baseline values and test statistics in some of the included trials necessitated imputation of several data points. We overcame this problem by selecting a conservative correlation (rϭ0.5) between treatment and control end values, according to the methods proposed by Elbourne et al, 31 and then performed sensitivity analyses at 2 other levels (0.25 and 0.75). Lastly, subgroup analysis at 0.25 and 0.75 changed some subgroups from nonsignificant to significant. This finding may suggest a lack of robustness in the data.
Perspectives
Most concerns regarding the adverse effects of fructose on BP are based on results of studies using rat models [7] [8] [9] [10] and acute human studies. 13, 16, 18 The present meta-analysis, however, shows a significant DBP-and MAP-lowering effect and a trend favoring SBP in the overall analysis and in the nondiabetic stratum when fructose was exchanged isocalorically for other carbohydrates. Given the small participant pool in our analyses, larger and longer human trials are needed to gain a better assessment of the effect of fructose on BP. Because elevated uric acid has been proposed as a mediator of the effects of fructose on BP, future meta-analyses of human trials should also consider this end point. These trials will help resolve whether the potential role of fructose in the development of the hypertension epidemic should be reconsidered. " Differences between subgroups were tested using meta-regression and the significance level was reported as p-value, where p>0.05 is considered to be significant.
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